12. Referanser

Adeniran, A. J., Shuch, B., & Humphrey, P. A. (2024). Sarcomatoid and Rhabdoid Renal Cell Carcinoma: Clinical, Pathologic, and Molecular Genetic Features. American Journal of Surgical Pathology, 48(7), e65-e88.

Albiges, L., Gurney, H. P., Atduev, V., Suárez, C., Climent Duran, M. A., Pook, D., Tomczak, P., Barthelemy, P., ... Lee, C. H. (2022). 1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). Annals of Oncology, 33, S1204-S1205.

Albiges, L., Rini, B. I., Peltola, K., De Velasco Oria, G. A., Burotto, M., Suarez Rodriguez, C., Ghatalia, P., Iacovelli, R., ... Choueiri, T. K. (2023). LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study. Annals of Oncology, 34(Supplement 2), S1329-S1330.

Albiges, L., Motzer, R. J., Trevino, S., Kanesvaran, R., Centkowski, P., Reimers, M. A., Sade, J. P., Pouessel, D., ... Powles, T. (2025). Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. Journal of Clinical Oncology, 43(5 suppl), 438-438.

Algaba, F., Arce, Y., López-Beltrán, A., Montironi, R., Mikuz, G., & Bono, A. V. (2005). Intraoperative frozen section diagnosis in urological oncology. European Urology, 47(2), 129-36.

Amin, M. B., Edge, S. B., Greene, F. L., Byrd, R. B., Brookland, R. K., Washington, M. K., ... Gershenwald, J. E. (2017). AJCC Cancer Staging Manual. Springer.

Andrews, J. R., Atwell, T., Schmit, G., Lohse, C. M., Kurup, A. N., Weisbrod, A., Callstrom, M. R., Cheville, J. C., ... Thompson, R. H. (2019). Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. European Urology, 76(2), 244-251.

Aoyama, H., Tago, M., & Shirato, H. (2015). Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial. JAMA Oncology, 1(4), 457-64.

Appleman, L. J., Puligandla, M., Pal, S. K., Harris, W., Agarwal, N., Costello, B. A., Ryan, C. W., Pins, M., ... Carducci, M. A. (2019). Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). Journal of Clinical Oncology, 37(15_suppl), 4502.

Armstrong, A. J., Halabi, S., Eisen, T., Broderick, S., Stadler, W. M., Jones, R. J., Garcia, J. A., Vaishampayan, U. N., ... George, D. J. (2016). Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. The Lancet. Oncology, 17(3), 378-388.

Auvray, M., Auclin, E., Barthelemy, P., Bono, P., Kellokumpu-Lehtinen, P., Gross-Goupil, M., De Velasco, G., Powles, T., ... Albiges, L. (2019). Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. European Journal of Cancer, 108, 33-40.

Avulova, S., Cheville, J. C., Lohse, C. M., Gupta, S., Potretzke, T. A., Tsivian, M., Thompson, R. H., Boorjian, S. A., ... Potretzke, A. M. (2021). Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. European Urology, 79(2), 225-231.

Barr, R. G., Peterson, C., & Hindi, A. (2014). Evaluation of indeterminate renal masses with contrast-enhanced US: a diagnostic performance study. Radiology, 271(1), 133-42.

Basile, G., Fallara, G., Verri, P., Uleri, A., Chiti, A., Gianolli, L., Pepe, G., Tedde, A., ... Breda, A. (2024). The Role of (99m)Tc-Sestamibi Single-photon Emission Computed Tomography/Computed Tomography in the Diagnostic Pathway for Renal Masses: A Systematic Review and Meta-analysis. European Urology, 85(1), 63-71.

Beckermann, K. E., Sharma, D., Chaturvedi, S., Msaouel, P., Abboud, M. R., Allory, Y., Bourdeaut, F., Calderaro, J., ... Rathmell, W. K. (2017). Renal Medullary Carcinoma: Establishing Standards in Practice. Journal of Oncology Practice, 13(7), 414-421.

Beisland, C., Gudbrandsdottir, G., Reisæter, L. A., Bostad, L., Wentzel-Larsen, T., & Hjelle, K. M. (2015). Contemporary external validation of the Leibovich model for prediction of progression after radical surgery for clear cell renal cell carcinoma. Scandinavian Journal of Urology, 49(3), 205-10.

Beisland, E., Beisland, C., Hjelle, K. M., Bakke, A., Aarstad, A. K., & Aarstad, H. J. (2015). Health-related quality of life, personality and choice of coping are related in renal cell carcinoma patients. Scandinavian Journal of Urology, 49(4), 282-9.

Beisland, C., Medby, P. C., & Beisland, H. O. (2004). Presumed radically treated renal cell carcinoma--recurrence of the disease and prognostic factors for subsequent survival. Scandinavian Journal of Urology and Nephrology, 38(4), 299-305.

Beisland, C., Guðbrandsdottir, G., Reisæter, L. A., Bostad, L., & Hjelle, K. M. (2016). A prospective risk-stratified follow-up programme for radically treated renal cell carcinoma patients: evaluation after eight years of clinical use. World Journal of Urology, 34(8), 1087-99.

Beitler, J. J., Makara, D., Silverman, P., & Lederman, G. (2004). Definitive, high-dose-per-fraction, conformal, stereotactic external radiation for renal cell carcinoma. American Journal of Clinical Oncology, 27(6), 646-8.

Bergmann, L., Albiges, L., Ahrens, M., Gross-Goupil, M., Boleti, E., Gravis, G., Fléchon, A., Grimm, M. O., ... Haanen, J. B. (2025). Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial. Annals of Oncology, 36(7), 796-806.

Bertolotto, M., Cicero, C., Perrone, R., Degrassi, F., Cacciato, F., & Cova, M. A. (2015). Renal Masses With Equivocal Enhancement at CT: Characterization With Contrast-Enhanced Ultrasound. AJR: American Journal of Roentgenology, 204(5), W557-65.

Bex, A., Albiges, L., Bedke, J., Capitanio, U., Dabestani, S., Hora, M., ... Klatte, T. (2025). Renal Cell Carcinoma Arnhem: EAU. Hentet fra https://uroweb.org/guidelines/renal-cell-carcinoma

Bex, A., Mulders, P., Jewett, M., Wagstaff, J., van Thienen, J. V., Blank, C. U., van Velthoven, R., Del Pilar Laguna, M., ... Haanen, J. (2019). Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncology, 5(2), 164-170.

Bhindi, B., Abel, E. J., Albiges, L., Bensalah, K., Boorjian, S. A., Daneshmand, S., Karam, J. A., Mason, R. J., ... Bex, A. (2019). Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. European Urology, 75(1), 111-128.

Bissada, N. K., Yakout, H. H., Babanouri, A., Elsalamony, T., Fahmy, W., Gunham, M., Hull, G. W., & Chaudhary, U. B. (2003). Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology, 61(1), 89-92.

Blom, J. H., van Poppel, H., Maréchal, J. M., Jacqmin, D., Schröder, F. H., de Prijck, L., & Sylvester, R. (2009). Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. European Urology, 55(1), 28-34.

Blute, M. L., Leibovich, B. C., Lohse, C. M., Cheville, J. C., & Zincke, H. (2004). The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU International, 94(1), 33-41.

Blute, M. L., Boorjian, S. A., Leibovich, B. C., Lohse, C. M., Frank, I., & Karnes, R. J. (2007). Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy. Journal of Urology, 178(2), 440-5; discussion 444.

Borregales, L. D., Kim, D. Y., Staller, A. L., Qiao, W., Thomas, A. Z., Adibi, M., Tamboli, P., Sircar, K., ... Karam, J. A. (2016). Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology, 34(5), 237.e19-26.

Brassier, M., Khene, Z. E., Bernhard, J. C., Dang, V. T., Ouzaid, I., Nouhaud, F. X., Olivier, J., Nedelcu, C., ... Bigot, P. (2022). Percutaneous Ablation Versus Surgical Resection for Local Recurrence Following Partial Nephrectomy for Renal Cell Cancer: A Propensity Score Analysis (REPART Study-UroCCR 71). European Urology Focus, 8(1), 210-216.

Breda, A., Finelli, A., Janetschek, G., Porpiglia, F., & Montorsi, F. (2009). Complications of laparoscopic surgery for renal masses: prevention, management, and comparison with the open experience. European Urology, 55(4), 836-50.

Brierley, J. D., Gospodarowicz, M. K., Wittekind, C. (2017). TNM Classification of Malignant Tumours. Wiley-Blackwell.

Bui, T. O., Dao, V. T., Nguyen, V. T., Feugeas, J. P., Pamoukdjian, F., & Bousquet, G. (2022). Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis. European Urology, 81(4), 349-361.

The Calculator (24. Januar 2016). Karnofsky score for performance status calculator. [nettressurs]. [s.l.]: Thecalculator.co. Hentet 03. oktober 2022 fra https://www.thecalculator.co/health/Karnofsky-Score-for-Performance-Status-Calculator-961.html

Campbell, S. C., Clark, P. E., Chang, S. S., Karam, J. A., Souter, L., & Uzzo, R. G. (2021). Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. Journal of Urology, 206(2), 199-208.

Campbell, S. C., Uzzo, R. G., Karam, J. A., Chang, S. S., Clark, P. E., & Souter, L. (2021). Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. Journal of Urology, 206(2), 209-218.

Campi, R., Berni, A., Amparore, D., Bertolo, R., Capitanio, U., Carbonara, U., Erdem, S., Ingels, A., ... Esperto, F. (2022). Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: a systematic review. Minerva urology and nephrology, 74(2), 146-160.

Cancel, M., Fromont, G., Blonz, C., Chevreau, C., Rioux-Leclercq, N., Laguerre, B., Oudard, S., Gross-Goupil, M., ... Albiges, L. (2021). Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales). European Journal of Cancer, 158, 1-11.

Capitanio, U., Bensalah, K., Bex, A., Boorjian, S. A., Bray, F., Coleman, J., Gore, J. L., Sun, M., ... Russo, P. (2019). Epidemiology of Renal Cell Carcinoma. European Urology, 75(1), 74-84.

Capitanio, U., Larcher, A., Cianflone, F., Trevisani, F., Nini, A., Mottrie, A., Mari, A., Campi, R., ... Bertini, R. (2020). Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. European Urology Oncology, 3(2), 209-215.

Carlo, M. I., Mukherjee, S., Mandelker, D., Vijai, J., Kemel, Y., Zhang, L., Knezevic, A., Patil, S., ... Offit, K. (2018). Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 4(9), 1228-1235.

Charlson, M., Szatrowski, T. P., Peterson, J., & Gold, J. (1994). Validation of a combined comorbidity index. Journal of Clinical Epidemiology, 47(11), 1245-51.

Choi, J. E., You, J. H., Kim, D. K., Rha, K. H., & Lee, S. H. (2015). Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta-analysis. European Urology, 67(5), 891-901.

Choudhary, S., Rajesh, A., Mayer, N. J., Mulcahy, K. A., & Haroon, A. (2009). Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms. Clinical Radiology, 64(5), 517-22.

Choueiri, T. K., Albigès, L., McDermott, D. F., Hammers, H. J., Escudier, B., Burotto, M., Plimack, E. R., Porta, C., ... Motzer, R. J. (2026). Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial. Annals of Oncology, 37(7), 960-973.

Choueiri, T. K., Hessel, C., Halabi, S., Sanford, B., Michaelson, M. D., Hahn, O., Walsh, M., Olencki, T., ... Morris, M. J. (2018). Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. European Journal of Cancer, 94, 115-125.

Choueiri, T. K., Albiges, L., Barthélémy, P., Iacovelli, R., Emambux, S., Molina-Cerrillo, J., Garmezy, B., Barata, P., ... Motzer, R. J. (2024). Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. Lancet, 404(10460), 1309-1320.

Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., Hammers, H., Hutson, T. E., ... Motzer, R. J. (2015). Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 373(19), 1814-23.

Choueiri, T. K., Powles, T., Albiges, L., Burotto, M., Szczylik, C., Zurawski, B., Yanez Ruiz, E., Maruzzo, M., ... Motzer, R. J. (2023). Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. New England Journal of Medicine, 388(19), 1767-1778.

Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., ... Motzer, R. J. (2021). Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 384(9), 829-841.

Choueiri, T. K., Powles, T., Peltola, K., de Velasco, G., Burotto, M., Suarez, C., Ghatalia, P., Iacovelli, R., ... Rini, B. (2024). Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 391(8), 710-721.

Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Chang, Y. H., Hajek, J., Symeonides, S. N., ... Powles, T. (2021). Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. New England Journal of Medicine, 385(8), 683-694.

Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Chang, Y. H., ... Powles, T. (2024). Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. New England Journal of Medicine, 390(15), 1359-1371.

Chow, E., Zeng, L., Salvo, N., Dennis, K., Tsao, M., & Lutz, S. (2012). Update on the systematic review of palliative radiotherapy trials for bone metastases. Clinical Oncology, 24(2), 112-24.

Churilla, T. M., Ballman, K. V., Brown, P. D., Twohy, E. L., Jaeckle, K., Farace, E., Cerhan, J. H., Anderson, S. K., ... Asher, A. L. (2017). Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. International Journal of Radiation Oncology, Biology, Physics, 99(5), 1173-1178.

Corica, F. A., Iczkowski, K. A., Cheng, L., Zincke, H., Blute, M. L., Wendel, A., Sebo, T. J., Neumann, R., & Bostwick, D. G. (1999). Cystic renal cell carcinoma is cured by resection: a study of 24 cases with long-term followup. Journal of Urology, 161(2), 408-11.

Couture, F., Hadj-Mimoune, S., Michael, S., Podasca, T. B., Noël-Lamy, M., & Richard, P. O. (2023). Evolution of Bosniak IIF Renal Cysts and Impact of the 2019 Bosniak Classification. Journal of Urology, 209(4), 694-700.

Dabestani, S., Beisland, C., Stewart, G. D., Bensalah, K., Gudmundsson, E., Lam, T. B., Gietzmann, W., Zakikhani, P., ... Bex, A. (2019). Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. European Urology Focus, 5(5), 857-866.

Dabestani, S., Marconi, L., Hofmann, F., Stewart, F., Lam, T. B., Canfield, S. E., Staehler, M., Powles, T., ... Bex, A. (2014). Local treatments for metastases of renal cell carcinoma: a systematic review. The Lancet. Oncology, 15(12), e549-61.

Dabestani, S., Beisland, C., Stewart, G. D., Bensalah, K., Gudmundsson, E., Lam, T. B., Gietzmann, W., Zakikhani, P., ... Bex, A. (2019). Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scandinavian Journal of Urology, 53(1), 14-20.

Dabestani, S., Thorstenson, A., Lindblad, P., Harmenberg, U., Ljungberg, B., & Lundstam, S. (2016). Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World Journal of Urology, 34(8), 1081-6.

Delahunt, B., Cheville, J. C., Martignoni, G., Humphrey, P. A., Magi-Galluzzi, C., McKenney, J., Egevad, L., Algaba, F., ... Srigley, J. R. (2013). The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. American Journal of Surgical Pathology, 37(10), 1490-504.

Deng, R., Li, Y., & Zhang, Z. (2026). A Comparison of Ablation Therapy and Partial Nephrectomy for the Treatment of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Urologia Internationalis, Epub ahead of print, Jan 8. 1-25.

Dilauro, M., Quon, M., McInnes, M. D., Vakili, M., Chung, A., Flood, T. A., & Schieda, N. (2016). Comparison of Contrast-Enhanced Multiphase Renal Protocol CT Versus MRI for Diagnosis of Papillary Renal Cell Carcinoma. AJR: American Journal of Roentgenology, 206(2), 319-25.

Egbert, N. D., Caoili, E. M., Cohan, R. H., Davenport, M. S., Francis, I. R., Kunju, L. P., & Ellis, J. H. (2013). Differentiation of papillary renal cell carcinoma subtypes on CT and MRI. AJR: American Journal of Roentgenology, 201(2), 347-55.

Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A. (2019). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 30(5), 706-720.

Escudier, B., Molinie, V., Bracarda, S., Maroto, P., Szczylik, C., Nathan, P., Negrier, S., Weiss, C., ... Albiges, L. (2016). Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. European Journal of Cancer, 69, 226-235.

Ficarra, V., Novara, G., Secco, S., Macchi, V., Porzionato, A., De Caro, R., & Artibani, W. (2009). Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. European Urology, 56(5), 786-93.

Finelli, A., Cheung, D. C., Al-Matar, A., Evans, A. J., Morash, C. G., Pautler, S. E., Siemens, D. R., Tanguay, S., ... Jewett, M. A. S. (2020). Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. European Urology, 78(3), 460-467.

Flanigan, R. C., Mickisch, G., Sylvester, R., Tangen, C., Van Poppel, H., & Crawford, E. D. (2004). Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. Journal of Urology, 171(3), 1071-6.

Gershman, B., Thompson, R. H., Boorjian, S. A., Larcher, A., Capitanio, U., Montorsi, F., Carenzi, C., Bertini, R., ... Leibovich, B. C. (2018). Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. Journal of Urology, 199(5), 1143-1148.

Gorin, M. A., Rowe, S. P., Baras, A. S., Solnes, L. B., Ball, M. W., Pierorazio, P. M., Pavlovich, C. P., Epstein, J. I., ... Allaf, M. E. (2016). Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. European Urology, 69(3), 413-6.

Graham, J., Wells, J. C., Donskov, F., Lee, J. L., Fraccon, A., Pasini, F., Porta, C., Bowman, I. A., ... Heng, D. Y. C. (2019). Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2(6), 643-648.

Gratzke, C., Seitz, M., Bayrle, F., Schlenker, B., Bastian, P. J., Haseke, N., Bader, M., Tilki, D., ... Bachmann, A. (2009). Quality of life and perioperative outcomes after retroperitoneoscopic radical nephrectomy (RN), open RN and nephron-sparing surgery in patients with renal cell carcinoma. BJU International, 104(4), 470-5.

Gudbjartsson, T., Jónasdóttir, T. J., Thoroddsen, A., Einarsson, G. V., Jónsdóttir, G. M., Kristjánsson, K., Hardarson, S., Magnússon, K., ... Amundadóttir, L. T. (2002). A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. International Journal of Cancer, 100(4), 476-9.

Haas, N. B., Powles, T., Tomczak, P., Park, S. H., Venugopal, B., Symeonides, S. N., Ferguson, T., Chang, W. Y. H., ... Choueiri, T. K. (2025). Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology, 43(16 suppl), 4514.

Haas, N. B., Manola, J., Uzzo, R. G., Flaherty, K. T., Wood, C. G., Kane, C., Jewett, M., Dutcher, J. P., ... DiPaola, R. S. (2016). Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet, 387(10032), 2008-16.

Hahn, A. W., Chahoud, J., Skelton, W. P., Yuan, Y., Zurita-Saavedra, A. J., Kovitz, C., Alhalabi, O., Campbell, M. T., ... Tannir, N. M. (2026). A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo). Annals of Oncology, 37(2), 241-249.

Hemal, A. K., Kumar, A., Kumar, R., Wadhwa, P., Seth, A., & Gupta, N. P. (2007). Laparoscopic versus open radical nephrectomy for large renal tumors: a long-term prospective comparison. Journal of Urology, 177(3), 862-6.

Heng, D., Choueiri, T., Xie, W. ([s.a.]). IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma. [nettressurs]. [s.l.]: MDCalc. Hentet 06. oktober 2022 fra https://www.mdcalc.com/calc/3008/imdc-international-metastatic-rcc-database-consortium-risk-model-metastatic-renal-cell-carcinoma

Heng, D. Y., Wells, J. C., Rini, B. I., Beuselinck, B., Lee, J. L., Knox, J. J., Bjarnason, G. A., Pal, S. K., ... Choueiri, T. K. (2014). Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 66(4), 704-10.

Heng, D. Y., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., ... Choueiri, T. K. (2009). Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Journal of Clinical Oncology, 27(34), 5794-9.

Henry, D. H., Costa, L., Goldwasser, F., Hirsh, V., Hungria, V., Prausova, J., Scagliotti, G. V., Sleeboom, H., ... Yeh, H. (2011). Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology, 29(9), 1125-32.

Hjelle, K. M., Johannesen, T. B., & Beisland, C. (2017). Postoperative 30-day Mortality Rates for Kidney Cancer Are Dependent on Hospital Surgical Volume: Results from a Norwegian Population-based Study. European Urology Focus, 3(2-3), 300-307.

Hoskin, P. J., Hopkins, K., Misra, V., Holt, T., McMenemin, R., Dubois, D., McKinna, F., Foran, B., ... Lopes, A. (2019). Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial. JAMA, 322(21), 2084-2094.

Huang, W. C., Donin, N. M., Levey, A. S., & Campbell, S. C. (2020). Chronic Kidney Disease and Kidney Cancer Surgery: New Perspectives. Journal of Urology, 203(3), 475-485.

Huang, W. C., Elkin, E. B., Levey, A. S., Jang, T. L., & Russo, P. (2009). Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes?. Journal of Urology, 181(1), 55-61; discussion 61-2.

Huang, R. S., Chow, R., Benour, A., Chen, D., Boldt, G., Wallis, C. J. D., Swaminath, A., Simone, C. B. ,. 2., ... Raman, S. (2025). Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis. The Lancet. Oncology, 26(3), 387-398.

Huang, W. C., Levey, A. S., Serio, A. M., Snyder, M., Vickers, A. J., Raj, G. V., Scardino, P. T., & Russo, P. (2006). Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. The Lancet. Oncology, 7(9), 735-40.

Hunter, G. K., Balagamwala, E. H., Koyfman, S. A., Bledsoe, T., Sheplan, L. J., Reddy, C. A., Chao, S. T., Djemil, T., ... Videtic, G. M. M. (2012). The efficacy of external beam radiotherapy and stereotactic body radiotherapy for painful spinal metastases from renal cell carcinoma. Practical Radiation Oncology, 2(4), e95-e100.

Hutson, T. E., Michaelson, M. D., Kuzel, T. M., Agarwal, N., Molina, A. M., Hsieh, J. J., Vaishampayan, U. N., Xie, R., ... Fishman, M. N. (2021). A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. European Urology, 80(2), 162-170.

Ingrosso, G., Becherini, C., Francolini, G., Lancia, A., Alì, E., Caini, S., Teriaca, M. A., Marchionni, A., ... Detti, B. (2021). Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: A systematic review. Critical Reviews in Oncology/Hematology, 159, 103242.

Jeong, I. G., Khandwala, Y. S., Kim, J. H., Han, D. H., Li, S., Wang, Y., Chang, S. L., & Chung, B. I. (2017). Association of Robotic-Assisted vs Laparoscopic Radical Nephrectomy With Perioperative Outcomes and Health Care Costs, 2003 to 2015. JAMA, 318(16), 1561-1568.

Johnson, D. C., Vukina, J., Smith, A. B., Meyer, A. M., Wheeler, S. B., Kuo, T. M., Tan, H. J., Woods, M. E., ... Nielsen, M. E. (2015). Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. Journal of Urology, 193(1), 30-5.

Kanesvaran, R., Le Saux, O., Motzer, R., Choueiri, T. K., Scotté, F., Bellmunt, J., & Launay-Vacher, V. (2018). Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. The Lancet. Oncology, 19(6), e317-e326.

Kang, S. K., Huang, W. C., Pandharipande, P. V., & Chandarana, H. (2014). Solid renal masses: what the numbers tell us. AJR: American Journal of Roentgenology, 202(6), 1196-206.

Karellas, M. E., Jang, T. L., Kagiwada, M. A., Kinnaman, M. D., Jarnagin, W. R., & Russo, P. (2009). Advanced-stage renal cell carcinoma treated by radical nephrectomy and adjacent organ or structure resection. BJU International, 103(2), 160-4.

Karolinska University Hospital (2024-2037). Resection or Ablation of Small Kidney Tumors (RESTART) [pågående studie]. (NCT06278506). Hentet fra https://clinicaltrials.gov/study/NCT06278506

Klatte, T., Rossi, S. H., & Stewart, G. D. (2018). Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World Journal of Urology, 36(12), 1943-1952.

Knox, J. J., Barrios, C. H., Kim, T. M., Cosgriff, T., Srimuninnimit, V., Pittman, K., Sabbatini, R., Rha, S. Y., ... Motzer, R. J. (2017). Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC. Annals of Oncology, 28(6), 1339-1345.

Ko, J. J., Xie, W., Kroeger, N., Lee, J. L., Rini, B. I., Knox, J. J., Bjarnason, G. A., Srinivas, S., ... Heng, D. Y. (2015). The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. The Lancet. Oncology, 16(3), 293-300.

Kunkle, D. A., Egleston, B. L., & Uzzo, R. G. (2008). Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. Journal of Urology, 179(4), 1227-33; discussion 1233-4.

Kutikov, A., & Uzzo, R. G. (2009). The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. Journal of Urology, 182(3), 844-53.

Laird, A., Choy, K. C., Delaney, H., Cutress, M. L., O'Connor, K. M., Tolley, D. A., McNeill, S. A., Stewart, G. D., & Riddick, A. C. (2015). Matched pair analysis of laparoscopic versus open radical nephrectomy for the treatment of T3 renal cell carcinoma. World Journal of Urology, 33(1), 25-32.

Lane, B. R., Abouassaly, R., Gao, T., Weight, C. J., Hernandez, A. V., Larson, B. T., Kaouk, J. H., Gill, I. S., & Campbell, S. C. (2010). Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer, 116(13), 3119-26.

Lane, B. R., Tiong, H. Y., Campbell, S. C., Fergany, A. F., Weight, C. J., Larson, B. T., Novick, A. C., & Flechner, S. M. (2009). Management of the adrenal gland during partial nephrectomy. Journal of Urology, 181(6), 2430-6; discussion 2436-7.

Lara, P. N. ,. J., Tangen, C., Heath, E. I., Gulati, S., Stein, M. N., Meng, M., Alva, A. S., Pal, S. K., ... Ryan, C. W. (2024). Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. European Urology, 86(3), 258-264.

Larcher, A., Dell'Oglio, P., Fossati, N., Nini, A., Muttin, F., Suardi, N., De Cobelli, F., Salonia, A., ... Capitanio, U. (2017). When to perform preoperative chest computed tomography for renal cancer staging. BJU International, 120(4), 490-496.

Lardas, M., Stewart, F., Scrimgeour, D., Hofmann, F., Marconi, L., Dabestani, S., Bex, A., Volpe, A., ... Lam, T. B. (2016). Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. European Urology, 70(2), 265-80.

Larsen, I. K. (2022). Cancer in Norway 2021 - Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Larsen, I. K. (2024). Cancer in Norway 2023: cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Larsen, I. K., Aagnes, B., Breivik, S., Hestad, J. J., Jakobsen, E., Johannesen, T. B., ... Lambert, P. C. (2026). Cancer in Norway 2025: cancer incidence, mortality, survival and prevalence in Norway Oslo: Norwegian Institute of Public Health - Cancer Registry of Norway. Hentet fra https://www.fhi.no/en/publ/2026/cancer-in-norway-2025/

Lee, J., Hodgson, D., Chow, E., Bezjak, A., Catton, P., Tsuji, D., O'Brien, M., Danjoux, C., ... Gospodarowicz, M. K. (2005). A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer, 104(9), 1894-900.

Lee, C. H., Voss, M. H., Carlo, M. I., Chen, Y. B., Zucker, M., Knezevic, A., Lefkowitz, R. A., Shapnik, N., ... Motzer, R. J. (2022). Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. Journal of Clinical Oncology, 40(21), 2333-2341.

Lee, C. H., Shah, A. Y., Rasco, D., Rao, A., Taylor, M. H., Di Simone, C., Hsieh, J. J., Pinto, A., ... Motzer, R. J. (2021). Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. The Lancet. Oncology, 22(7), 946-958.

Leibovich, B. C., Blute, M. L., Cheville, J. C., Lohse, C. M., Frank, I., Kwon, E. D., Weaver, A. L., Parker, A. S., & Zincke, H. (2003). Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer, 97(7), 1663-71.

Leibovich, B. C., Lohse, C. M., Cheville, J. C., Zaid, H. B., Boorjian, S. A., Frank, I., Thompson, R. H., & Parker, W. P. (2018). Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. European Urology, 73(5), 772-780.

Li, K. P., Wan, S., Chen, S. Y., Wang, C. Y., Liu, S. H., & Yang, L. (2024). Perioperative, functional and oncologic outcomes of percutaneous ablation versus minimally invasive partial nephrectomy for clinical T1 renal tumors: outcomes from a pooled analysis. Journal of Robotic Surgery, 18(1), 306.

Liu, Y., Wang, L., Bao, E. H., Wang, L., Wang, J. H., Yang, L., & Zhu, P. Y. (2024). Perioperative, functional, and oncological outcomes after cryoablation or partial nephrectomy for small renal masses in solitary kidneys: a systematic review and meta-analysis. BMC Urology, 24(1), 19.

Liu, Z., Zhang, L., Hong, P., Li, L., Tang, S., Zhao, X., Zhang, Q., Zhu, G., ... Ma, L. (2020). The influence of venous tumor thrombus combined with bland thrombus on the surgical treatment and prognosis of renal cell carcinoma patients. Cancer medicine, 9(16), 5860-5868.

Liu, H., Kong, Q. F., Li, J., Wu, Y. Q., Pan, K. H., Xu, B., Wang, Y. L., & Chen, M. (2021). A meta-analysis for comparison of partial nephrectomy vs. radical nephrectomy in patients with pT3a renal cell carcinoma. Translational andrology and urology, 10(3), 1170-1178.

Ljungberg, B., Albiges, L., Bedke, J., Bex, A., Capitanio, U., Giles, R. H., ... Hora, M. (2022). Renal Cell Carcinoma Arnhem: EAU.

Ljungberg, B., Alamdari, F. I., Rasmuson, T., & Roos, G. (1999). Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU International, 84(4), 405-11.

Ljungberg, B., Sundqvist, P., Lindblad, P., Kjellman, A., Thorstenson, A., Hellström, M., Kröger Dahlin, B. I., Thomasson, M., ... Lundstam, S. (2020). Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting. Scandinavian Journal of Urology, 54(6), 487-492.

Loft, A., Hesse, B., Birk Christensen, C. (2011). Klinisk nuklearmedicin (2 utg.) [s.l.]: Dansk selskab for klinisk fysiologi og nuklearmedicin.

Lu, Q., Zhao, X., Zhang, S., Wang, G., Ji, C., Liu, G., Fu, Y., Xu, L., ... Guo, H. (2024). Robot-assisted Simple Enucleation Versus Standard Robot-assisted Partial Nephrectomy for Low- or Intermediate-complexity, Clinical T1 Renal Tumors: A Randomized Controlled Noninferiority Trial. European Urology Oncology, 7(2), 275-281.

Lucocq, J., Pillai, S., Oparka, R., & Nabi, G. (2021). . European Radiology, 31(2), 901-908.

Lui, S. T., & Shuch, B. (2019). Genetic Testing in Kidney Cancer Patients: Who, When, and How?. European Urology Focus, 5(6), 973-976.

MacLennan, S., Imamura, M., Lapitan, M. C., Omar, M. I., Lam, T. B., Hilvano-Cabungcal, A. M., Royle, P., Stewart, F., ... N'Dow, J. (2012). Systematic review of oncological outcomes following surgical management of localised renal cancer. European Urology, 61(5), 972-93.

Marconi, L., Dabestani, S., Lam, T. B., Hofmann, F., Stewart, F., Norrie, J., Bex, A., Bensalah, K., ... Volpe, A. (2016). Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. European Urology, 69(4), 660-673.

Margulis, V., Sánchez-Ortiz, R. F., Tamboli, P., Cohen, D. D., Swanson, D. A., & Wood, C. G. (2007). Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer, 109(10), 2025-30.

Mason, R. J., Abdolell, M., Trottier, G., Pringle, C., Lawen, J. G., Bell, D. G., Jewett, M. A., Klotz, L., & Rendon, R. A. (2011). Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. European Urology, 59(5), 863-7.

McDermott, D. F., Lee, J. L., Ziobro, M., Suarez, C., Langiewicz, P., Matveev, V. B., Wiechno, P., Gafanov, R. A., ... Atkins, M. B. (2021). Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 39(9), 1029-1039.

McNichols, D. W., Segura, J. W., & DeWeerd, J. H. (1981). Renal cell carcinoma: long-term survival and late recurrence. Journal of Urology, 126(1), 17-23.

Méjean, A., Ravaud, A., Thezenas, S., Colas, S., Beauval, J. B., Bensalah, K., Geoffrois, L., Thiery-Vuillemin, A., ... Escudier, B. (2018). Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 379(5), 417-427.

Menko, F. H., van Steensel, M. A., Giraud, S., Friis-Hansen, L., Richard, S., Ungari, S., Nordenskjöld, M., Hansen, T. V., ... Maher, E. R. (2009). Birt-Hogg-Dubé syndrome: diagnosis and management. The Lancet. Oncology, 10(12), 1199-206.

Millet, I., Doyon, F. C., Hoa, D., Thuret, R., Merigeaud, S., Serre, I., & Taourel, P. (2011). Characterization of small solid renal lesions: can benign and malignant tumors be differentiated with CT?. AJR: American Journal of Roentgenology, 197(4), 887-96.

Mir, M. C., Derweesh, I., Porpiglia, F., Zargar, H., Mottrie, A., & Autorino, R. (2017). Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. European Urology, 71(4), 606-617.

Moch, H., Cubilla, A. L., Humphrey, P. A., Reuter, V. E., & Ulbright, T. M. (2016). The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. European Urology, 70(1), 93-105.

Motzer, R. J., Tannir, N. M., McDermott, D. F., Burotto, M., Choueiri, T. K., Hammers, H. J., Plimack, E. R., Porta, C. G., ... Escudier, B. (2021). 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). Annals of Oncology, 32(Suppl_5), S685-S687.

Motzer, R. J., Escudier, B., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Plimack, E. R., ... Tannir, N. M. (2020). Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer, 126(18), 4156-4167.

Motzer, R. J., Haas, N. B., Donskov, F., Gross-Goupil, M., Varlamov, S., Kopyltsov, E., Lee, J. L., Melichar, B., ... Sternberg, C. N. (2017). Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. Journal of Clinical Oncology, 35(35), 3916-3923.

Motzer, R. J., Park, S. H., McDermott, R. S., Porta, C., Heng, D. Y. C., Burotto, M., Iacovelli, R., Verzoni, E., ... Schmidinger, M. (2026). Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study. Journal of Clinical Oncology, 44(7_suppl), LBA417-LBA417.

Motzer, R. J., Russo, P., Grünwald, V., Tomita, Y., Zurawski, B., Parikh, O., Buti, S., Barthélémy, P., ... Bex, A. (2023). Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet, 401(10379), 821-832.

Motzer, R. J., Hutson, T. E., Glen, H., Michaelson, M. D., Molina, A., Eisen, T., Jassem, J., Zolnierek, J., ... Larkin, J. (2015). Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. The Lancet. Oncology, 16(15), 1473-1482.

Motzer, R., Alekseev, B., Rha, S. Y., Porta, C., Eto, M., Powles, T., Grünwald, V., Hutson, T. E., ... Choueiri, T. K. (2021). Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 384(14), 1289-1300.

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., ... Sharma, P. (2015). Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 373(19), 1803-13.

Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., ... Escudier, B. (2018). Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 378(14), 1277-1290.

Mucci, L. A., Hjelmborg, J. B., Harris, J. R., Czene, K., Havelick, D. J., Scheike, T., Graff, R. E., Holst, K., ... Collaboration, f. t. N. T. S. o. C. (2016). Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. JAMA, 315(1), 68-76.

Mulvenna, P., Nankivell, M., Barton, R., Faivre-Finn, C., Wilson, P., McColl, E., Moore, B., Brisbane, I., ... Langley, R. E. (2016). Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet, 388(10055), 2004-2014.

Muselaers, S., Erdem, S., Bertolo, R., Ingels, A., Kara, Ö., Pavan, N., Roussel, E., Pecoraro, A., ... On Behalf Of The European Association Of Urology Eau Young Academic Urologists Yau Renal Cancer Working, G. (2022). PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature. Journal of clinical medicine, 11(7)

NCCN (2013). PET PROS: PET professional resourves and outreach score: Part I: NCCN Practice Guidelines Tabular Summary (DD 3/20/13) Plymouth Meeting: NCCN. Hentet fra http://s3.amazonaws.com/rdcms-snmmi/files/production/public/docs/PET_PROS/NCCNPracticeGuidelinesI.pdf

Nguyen, K. A., Syed, J. S., Espenschied, C. R., LaDuca, H., Bhagat, A. M., Suarez-Sarmiento, A., O'Rourke, T. K. ,. J., Brierley, K. L., ... Shuch, B. (2017). Advances in the diagnosis of hereditary kidney cancer: Initial results of a multigene panel test. Cancer, 123(22), 4363-4371.

Northrup, H., Aronow, M. E., Bebin, E. M., Bissler, J., Darling, T. N., de Vries, P. J., Frost, M. D., Fuchs, Z., ... Krueger, D. A. (2021). Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 123, 50-66.

Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5(6), 649-55.

Olsen, T. K. (18. januar 2019). Målrettet kreftbehandling. Store medisinske leksikon [nettdokument]. Oslo: Store norske leksikon. Hentet 06. oktober 2022 fra https://sml.snl.no/m%C3%A5lrettet_kreftbehandling

Olson, J. J., Kalkanis, S. N., & Ryken, T. C. (2019). Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Treatment of Adults With Metastatic Brain Tumors: Executive Summary. Neurosurgery, 84(3), 550-552.

Ornstein, M. C., Pal, S. K., Wood, L. S., Tomer, J. M., Hobbs, B. P., Jia, X. S., Allman, K. D., Martin, A., ... Rini, B. I. (2019). Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. The Lancet. Oncology, 20(10), 1386-1394.

Osterman, C. K., Deal, A. M., Milowsky, M. I., Bjurlin, M. A., & Rose, T. L. (2020). Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma. Kidney Cancer, 4(3), 131-137.

Pal, S. K., Albiges, L., Tomczak, P., Suárez, C., Voss, M. H., de Velasco, G., Chahoud, J., Mochalova, A., ... Choueiri, T. K. (2023). Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet, 402(10397), 185-195.

Pal, S. K., Uzzo, R., Karam, J. A., Master, V. A., Donskov, F., Suarez, C., Albiges, L., Rini, B., ... Bex, A. (2022). Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet, 400(10358), 1103-1116.

Patchell, R. A., Tibbs, P. A., Regine, W. F., Payne, R., Saris, S., Kryscio, R. J., Mohiuddin, M., & Young, B. (2005). Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet, 366(9486), 643-8.

Patel, H. D., Druskin, S. C., Rowe, S. P., Pierorazio, P. M., Gorin, M. A., & Allaf, M. E. (2017). Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU International, 119(5), 661-666.

Patel, N., Cranston, D., Akhtar, M. Z., George, C., Jones, A., Leiblich, A., Protheroe, A., & Sullivan, M. (2012). Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU International, 110(9), 1270-5.

Peyronnet, B., Tondut, L., Bernhard, J. C., Vaessen, C., Doumerc, N., Sebe, P., Pradere, B., Guillonneau, B., ... Bensalah, K. (2018). Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy outcomes: a multicentre study. BJU International, 121(6), 916-922.

Pierorazio, P. M., Johnson, M. H., Ball, M. W., Gorin, M. A., Trock, B. J., Chang, P., Wagner, A. A., McKiernan, J. M., & Allaf, M. E. (2015). Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. European Urology, 68(3), 408-15.

Pierorazio, P., McKiernan, J., & Allaf, M. (2013). 633 Quality of life on active surveillance for small masses versus immediate intervention: interim analysis of the DISSRM (delayed intervention and surveillance for small renal masses) registry. Journal of Urology, 189(4S), e259.

Pillay, B., Wootten, A. C., Crowe, H., Corcoran, N., Tran, B., Bowden, P., Crowe, J., & Costello, A. J. (2016). The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews, 42, 56-72.

Procopio, G., Apollonio, G., Cognetti, F., Miceli, R., Milella, M., Mosca, A., Chiuri, V. E., Bearz, A., ... Verzoni, E. (2019). Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study. European Urology Oncology, 2(6), 699-707.

Quivy, A., Daste, A., Harbaoui, A., Duc, S., Bernhard, J. C., Gross-Goupil, M., & Ravaud, A. (2013). Optimal management of renal cell carcinoma in the elderly: a review. Clinical Interventions in Aging, 8, 433-42.

Rades, D., Conde-Moreno, A. J., Cacicedo, J., Šegedin, B., Stanic, K., Metz, M., Rudat, V., & Schild, S. E. (2018). Comparison of Two Radiotherapy Regimens for Metastatic Spinal Cord Compression: Subgroup Analyses from a Randomized Trial. Anticancer Research, 38(2), 1009-1015.

Rakic, I., Rakic, N., Stephens, A., Corsi, N., Davis, M., Tinsley, S., Butaney, M., Arora, S., ... Abdollah, F. (2023). Assessing the impact of lymphovascular invasion on overall survival in surgically treated renal cell carcinoma patients: A nationwide cohort analysis. Urologic Oncology, 41(10), 435.e1-435.e9.

Ravaud, A., Motzer, R. J., Pandha, H. S., George, D. J., Pantuck, A. J., Patel, A., Chang, Y. H., Escudier, B., ... Patard, J. J. (2016). Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. New England Journal of Medicine, 375(23), 2246-2254.

Regionalt cancercentrum (2022). Njurcancer: nationellt vårdprogram (Version: 5.1.). Stockholm: Regionala cancercentrum i samverkan. Hentet fra https://cancercentrum.se/samverkan/cancerdiagnoser/njure/vardprogram/

Regionalt cancercentrum (2022). Nationella kvalitetsregistret för njurcancer [nettdokument]. Stockholm: Regionala cancercentrum i samverkan. Hentet fra https://cancercentrum.se/samverkan/cancerdiagnoser/njure/kvalitetsregister/

Reichel, L. M., Pohar, S., Heiner, J., Buzaianu, E. M., & Damron, T. A. (2007). Radiotherapy to bone has utility in multifocal metastatic renal carcinoma. Clinical Orthopaedics and Related Research, 459, 133-138.

Riazalhosseini, Y., & Lathrop, M. (2016). Precision medicine from the renal cancer genome. Nat Rev Nephrol, 12(11), 655-666.

Rich, S. E., Chow, R., Raman, S., Liang Zeng, K., Lutz, S., Lam, H., Silva, M. F., & Chow, E. (2018). Update of the systematic review of palliative radiation therapy fractionation for bone metastases. Radiotherapy and Oncology, 126(3), 547-557.

Richard, P. O., Violette, P. D., Bhindi, B., Breau, R. H., Kassouf, W., Lavallée, L. T., Jewett, M., Kachura, J. R., ... Nayak, J. (2022). Canadian Urological Association guideline: Management of small renal masses - Full-text. Canadian Urological Association journal, 16(2), E61-e75.

Richard, P. O., Jewett, M. A., Bhatt, J. R., Kachura, J. R., Evans, A. J., Zlotta, A. R., Hermanns, T., Juvet, T., & Finelli, A. (2015). Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience. European Urology, 68(6), 1007-13.

Rini, B. I., Pal, S. K., Escudier, B. J., Atkins, M. B., Hutson, T. E., Porta, C., Verzoni, E., Needle, M. N., & McDermott, D. F. (2020). Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. The Lancet. Oncology, 21(1), 95-104.

Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., ... Powles, T. (2019). Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 380(12), 1116-1127.

Rodríguez-Fernández, I. A., Rodríguez-Romo, L., Hernandez-Barajas, D., Gonzalez-Conchas, G. A., Verdines-Perez, A., Templeton, A. J., Ocana, A., Seruga, B., ... Vera-Badillo, F. E. (2019). Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis. European Urology Oncology, 2(4), 448-455.

Rose, T. L., & Kim, W. Y. (2024). Renal Cell Carcinoma: A Review. JAMA, 332(12), 1001-1010.

Rosen, L. S., Gordon, D., Tchekmedyian, N. S., Yanagihara, R., Hirsh, V., Krzakowski, M., Pawlicki, M., De Souza, P., ... Seaman, J. (2004). Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer, 100(12), 2613-21.

Rosiello, G., Larcher, A., Fallara, G., Giancristofaro, C., Martini, A., Re, C., Cei, F., Musso, G., ... Capitanio, U. (2022). Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma. Urologic Oncology, 40(6), 271.e19-271.e27.

Samaratunga, H., Delahunt, B., Srigley, J. R., Berney, D. M., Cheng, L., Evans, A., Furusato, B., Leite, K. R. M., ... Egevad, L. (2020). Granular necrosis: a distinctive form of cell death in malignant tumours. Pathology, 52(5), 507-514.

Schieda, N., Krishna, S., Pedrosa, I., Kaffenberger, S. D., Davenport, M. S., & Silverman, S. G. (2022). Active Surveillance of Renal Masses: The Role of Radiology. Radiology, 302(1), 11-24.

Schoots, I. G., Zaccai, K., Hunink, M. G., & Verhagen, P. (2017). Bosniak Classification for Complex Renal Cysts Reevaluated: A Systematic Review. Journal of Urology, 198(1), 12-21.

Sebastià, C., Corominas, D., Musquera, M., Paño, B., Ajami, T., & Nicolau, C. (2020). Active surveillance of small renal masses. Insights Imaging, 11(1), 63.

Shah, A. Y., Karam, J. A., Malouf, G. G., Rao, P., Lim, Z. D., Jonasch, E., Xiao, L., Gao, J., ... Tannir, N. M. (2017). Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU International, 120(6), 782-792.

Shen, L., Yoon, L., Chung, B. I., Kamaya, A., & Tse, J. R. (2023). Outcomes of Bosniak Classification Version 2019 Class IIF Cystic Renal Masses at Imaging Surveillance. AJR: American Journal of Roentgenology, 220(5), 705-717.

Shirodkar, S. P., Ciancio, G., & Soloway, M. S. (2009). Words of wisdom. Re: Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. European Urology, 55(6), 1485-6.

Shuch, B., Vourganti, S., Ricketts, C. J., Middleton, L., Peterson, J., Merino, M. J., Metwalli, A. R., Srinivasan, R., & Linehan, W. M. (2014). Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. Journal of Clinical Oncology, 32(5), 431-7.

Silverman, S. G., Pedrosa, I., Ellis, J. H., Hindman, N. M., Schieda, N., Smith, A. D., Remer, E. M., Shinagare, A. B., ... Davenport, M. S. (2019). Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. Radiology, 292(2), 475-488.

Siva, S., Bressel, M., Sidhom, M., Sridharan, S., Vanneste, B. G. L., Davey, R., Montgomery, R., Ruben, J., ... Pryor, D. (2024). Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial. The Lancet. Oncology, 25(3), 308-316.

Smaldone, M. C., Kutikov, A., Egleston, B. L., Canter, D. J., Viterbo, R., Chen, D. Y., Jewett, M. A., Greenberg, R. E., & Uzzo, R. G. (2012). Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer, 118(4), 997-1006.

Soffietti, R., Kocher, M., Abacioglu, U. M., Villa, S., Fauchon, F., Baumert, B. G., Fariselli, L., Tzuk-Shina, T., ... Bottomley, A. (2013). A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. Journal of Clinical Oncology, 31(1), 65-72.

Soffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., Marosi, C., Metellus, P., ... Weller, M. (2017). Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO). Neuro-Oncology, 19(2), 162-174.

Srinivasan, R., Iliopoulos, O., Beckermann, K. E., Narayan, V., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., ... Jonasch, E. (2025). Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. The Lancet. Oncology, 26(5), 571-582.

Srinivasan, R., Gurram, S., Singer, E. A., Sidana, A., Al Harthy, M., Ball, M. W., Friend, J. C., Mac, L., ... Linehan, W. M. (2025). Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer. New England Journal of Medicine, 392(23), 2346-2356.

Steinberg, A. P., Finelli, A., Desai, M. M., Abreu, S. C., Ramani, A. P., Spaliviero, M., Rybicki, L., Kaouk, J., ... Gill, I. S. (2004). Laparoscopic radical nephrectomy for large (greater than 7 cm, T2) renal tumors. Journal of Urology, 172(6 Pt 1), 2172-6.

Stenman, M., Sinclair, G., Paavola, P., Wersäll, P., Harmenberg, U., & Lindskog, M. (2018). Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005-2014. Radiotherapy and Oncology, 127(3), 501-506.

Stewart, G. D., Welsh, S. J., Ursprung, S., Gallagher, F. A., Jones, J. O., Shields, J., Smith, C. G., Mitchell, T. J., ... Jones, R. J. (2022). A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). British Journal of Cancer, 127(6), 1051-1060.

Stewart-Merrill, S. B., Thompson, R. H., Boorjian, S. A., Psutka, S. P., Lohse, C. M., Cheville, J. C., Leibovich, B. C., & Frank, I. (2015). Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach. Journal of Clinical Oncology, 33(35), 4151-7.

Sun, M., Marconi, L., Eisen, T., Escudier, B., Giles, R. H., Haas, N. B., Harshman, L. C., Quinn, D. I., ... Bex, A. (2018). Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. European Urology, 74(5), 611-620.

Sun, M., Bianchi, M., Trinh, Q. D., Abdollah, F., Schmitges, J., Jeldres, C., Shariat, S. F., Graefen, M., ... Karakiewicz, P. I. (2012). Hospital volume is a determinant of postoperative complications, blood transfusion and length of stay after radical or partial nephrectomy. Journal of Urology, 187(2), 405-10.

Svedman, C., Karlsson, K., Rutkowska, E., Sandström, P., Blomgren, H., Lax, I., & Wersall, P. (2008). Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncologica, 47(8), 1578-83.

Svedman, C., Sandstrom, P., Pisa, P., Blomgren, H., Lax, I., Kalkner, K. M., Nilsson, S., & Wersall, P. (2006). A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncologica, 45(7), 870-875.

Tahbaz, R., Schmid, M., & Merseburger, A. S. (2018). Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Current opinion in urology, 28(1), 62-79.

Tames, A. V. C., Fonseca, E., Yamauchi, F. I., Arrais, G., de Andrade, T. C. M., & Baroni, R. H. (2019). Progression rate in Bosniak category IIF complex renal cysts. Radiologia brasileira, 52(3), 155-160.

Tang, C., Sherry, A. D., Seo, A., Hara, K., Choi, H., Liu, S., Sun, X., Montoya, A., ... Msaouel, P. (2025). Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial. The Lancet. Oncology, 26(10), 1289-1299.

Tannir, N. M., Signoretti, S., Choueiri, T. K., McDermott, D. F., Motzer, R. J., Flaifel, A., Pignon, J. C., Ficial, M., ... Rini, B. I. (2021). Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research, 27(1), 78-86.

Tannir, N. M., Jonasch, E., Albiges, L., Altinmakas, E., Ng, C. S., Matin, S. F., Wang, X., Qiao, W., ... Choueiri, T. K. (2016). Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. European Urology, 69(5), 866-74.

Testa, U., Pelosi, E., & Castelli, G. (2020). Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets. Medicines (Basel), 7(8)

Tikkinen, K. A. O., Cartwright, R., Gould, M. K., Naspro, R., Novara, G., Sandset, P. M., ... Violette, P. D. (2022). Thromboprophylaxis Arnhem: EAU. Hentet fra https://uroweb.org/guidelines/thromboprophylaxis

Tikkinen, K. A., Agarwal, A., Craigie, S., Cartwright, R., Gould, M. K., Haukka, J., Naspro, R., Novara, G., ... Guyatt, G. H. (2014). Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): introduction and methodology. Systematic reviews, 3, 150.

Townsend, P. W., Smalley, S. R., Cozad, S. C., Rosenthal, H. G., & Hassanein, R. E. (1995). Role of postoperative radiation therapy after stabilization of fractures caused by metastatic disease. International Journal of Radiation Oncology, Biology, Physics, 31(1), 43-9.

Trpkov, K., Grignon, D. J., Bonsib, S. M., Amin, M. B., Billis, A., Lopez-Beltran, A., Samaratunga, H., Tamboli, P., ... Srigley, J. R. (2013). Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations. American Journal of Surgical Pathology, 37(10), 1505-17.

Uzosike, A. C., Patel, H. D., Alam, R., Schwen, Z. R., Gupta, M., Gorin, M. A., Johnson, M. H., Gausepohl, H., ... Pierorazio, P. M. (2018). Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry. Journal of Urology, 199(3), 641-648.

van der Molen, A. J., Reimer, P., Dekkers, I. A., Bongartz, G., Bellin, M. F., Bertolotto, M., Clement, O., Heinz-Peer, G., ... Thomsen, H. S. (2018). Post-contrast acute kidney injury - Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. European Radiology, 28(7), 2845-2855.

van der Molen, A. J., Reimer, P., Dekkers, I. A., Bongartz, G., Bellin, M. F., Bertolotto, M., Clement, O., Heinz-Peer, G., ... Thomsen, H. S. (2018). Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients : Recommendations for updated ESUR Contrast Medium Safety Committee guidelines. European Radiology, 28(7), 2856-2869.

Van Poppel, H., Da Pozzo, L., Albrecht, W., Matveev, V., Bono, A., Borkowski, A., Colombel, M., Klotz, L., ... Sylvester, R. (2011). A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. European Urology, 59(4), 543-52.

Van Poppel, H., Da Pozzo, L., Albrecht, W., Matveev, V., Bono, A., Borkowski, A., Marechal, J. M., Klotz, L., ... Sylvester, R. (2007). A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. European Urology, 51(6), 1606-15.

Vasudev, N. S., Wilson, M., Stewart, G. D., Adeyoju, A., Cartledge, J., Kimuli, M., Datta, S., Hanbury, D., ... Banks, R. E. (2020). Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open, 10(5), e035938.

Volpe, A., Panzarella, T., Rendon, R. A., Haider, M. A., Kondylis, F. I., & Jewett, M. A. (2004). The natural history of incidentally detected small renal masses. Cancer, 100(4), 738-45.

Voss, M. H., Gurney, H., Atduev, V., Suarez, C., Climent, M. A., Pook, D., Tomczak, P., Barthélémy, P., ... Albiges, L. (2025). First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. European Urology, 88(6), 614-624.

Wang, Z. J., Westphalen, A. C., & Zagoria, R. J. (2018). CT and MRI of small renal masses. British Journal of Radiology, 91(1087), 20180131.

Wen, Z., Wang, L., Huang, J., Liu, Y., Chen, C. X., Wang, C. J., Chen, L. L., & Yang, X. S. (2023). Perioperative, functional, and oncologic outcomes after ablation or partial nephrectomy for solitary renal tumors: a systematic review and meta-analysis of comparative trials. Frontiers in Oncology, 13, 1202587.

Wersäll, P. J., Blomgren, H., Lax, I., Kälkner, K. M., Linder, C., Lundell, G., Nilsson, B., Nilsson, S., ... Svedman, C. (2005). Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiotherapy and Oncology, 77(1), 88-95.

Whelan, E. A., Mason, R. J., Himmelman, J. G., Matheson, K., & Rendon, R. A. (2019). Extended Duration of Active Surveillance of Small Renal Masses: A Prospective Cohort Study. Journal of Urology, 202(1), 57-61.

WHO Classification of Tumours Editorial Board (2022). Urinary and Male Genital Tumours (5 utg.) (WHO Classification of Tumours Volume 8). Lyon: IARC.

Winters, B. R., Gore, J. L., Holt, S. K., Harper, J. D., Lin, D. W., & Wright, J. L. (2015). Cystic renal cell carcinoma carries an excellent prognosis regardless of tumor size. Urologic Oncology, 33(12), 505.e9-13.

Wu, J. Y., Mi, Y., Liu, S., Yao, L., Tang, Q., He, Z. S., & Wang, X. Y. (2019). [Evaluating inferior vena cava wall invasion in renal cell carcinoma tumor thrombus with MRI]. Beijing Da Xue Xue Bao Yi Xue Ban, 51(4), 673-677 [på kinesisk].

Yoon, Y. E., Lee, H. H., Kim, K. H., Park, S. Y., Moon, H. S., Lee, S. R., Hong, Y. K., Park, D. S., & Kim, D. K. (2018). Focal therapy versus robot-assisted partial nephrectomy in the management of clinical T1 renal masses: A systematic review and meta-analysis. Medicine, 97(45), e13102.

Zhang, X., Liu, H., Liang, J., Zhao, J., Wang, Y., Chen, Y., Kang, D., Chen, Q., ... Zeng, H. (2025). Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial. JAMA Oncology, 11(10), 1169-1177.

Zisman, A., Wieder, J. A., Pantuck, A. J., Chao, D. H., Dorey, F., Said, J. W., Gitlitz, B. J., deKernion, J. B., ... Belldegrun, A. S. (2003). Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. Journal of Urology, 169(3), 909-16.